The Wall Street Transcript is a completely unique resource for investors and business researchers.

Let’s start with an overview of the company and some notable milestones. Mr. Levy: Sure. You know, a major challenge for cancer patients and their caregivers today is that while we’ve seen incredible ...

Let’s start with a look at your coverage, and how it might have changed since we spoke in 2023. Mr. Lichtman: Sure. I cover a large group of medical device companies from micro cap to mega cap. I ...

Today it was announced that pharmaceuticals are not exempt from Trump’s tariffs. How does this apply to medical devices? Are most devices manufactured offshore? Mr. Wittes: It’s company by company, ...

Please give us an overview of BioHarvest and its products and services. Mr. Sobel: I have the privilege of being CEO of BioHarvest Sciences. BioHarvest Sciences is the global leader in plant cell ...

Please tell us about Puma Biotechnology. Mr. Auerbach: I’d be more than happy to. Puma is a biotech company that is dedicated to the development and commercialization of drugs for the treatment of ...

How is your coverage weathering the tariff storm? Dr. Brozak: Our life sciences dedicated franchise, WBB Securities, is the busiest we’ve ever been in the history of the firm, and the life sciences ...

Vlad Vitoc, M.D., is Chairman of Board, Chief Executive Officer, and President of MAIA Biotechnology Inc. Dr. Vitoc has a broad array of experience across commercial strategic analysis and ...

Erez Aminov is the Chairman and Chief Executive Officer of MIRA Pharmaceuticals, Inc., a biopharmaceutical company developing treatments for neuropsychiatric disorders. In addition, Mr. Aminov ...

Cuong Do is President and CEO of BioVie Inc. Prior to his appointment with BioVie, Mr. Do was President of Samsung Global Strategy Group where he helped to set the strategic direction for Samsung ...

Hartaj Singh is a Founding Partner of Tecumseh Partners, advising biotech companies on valuation, strategy, and investor engagement. He also writes The Biotech Capital Compass, a newsletter ...